Skip to main content
Clinical Trials/IRCT20200517047485N1
IRCT20200517047485N1
Not yet recruiting
Phase 3

Evaluation of the efficacy and side effects of combination therapy of Kaletra and Hydroxychloroquine in comparison with Atazanavir / Ritonavir and Hydroxychloroquine in the treatment of patients with COVID-19

Arak University of Medical Sciences0 sites108 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Arak University of Medical Sciences
Enrollment
108
Status
Not yet recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients who are hospitalized in the ward and are considered to have a moderate form of COVID\-19 (need to be admitted to the ward and not ICU hospital)
  • Patients who are satisfied with the study entry

Exclusion Criteria

  • The patient has a severe disease that requires Ribavirin
  • The patient need to be hospitalized in the ICU or intubation
  • The patient has a mild form of the disease that does not require hospitalization (patients with a history of outpatient treatment for COVID\-19\).
  • Patients with specific underlying disease and / or need to take specific medications

Outcomes

Primary Outcomes

Not specified

Similar Trials